BCAN's Patient Handbook - Bladder Cancer Basics for the Newly Diagnosed



Donate Now to Support the Bladder Cancer Advocacy Network



Join The Online Bladder Cancer Support Community



The Bladder Cancer Advocacy Network (BCAN) is proud to announce that we have been designated a Marine Corps Marathon (MCM) Charity Partner! BCAN has been allocated 25 guaranteed entries for the 38th Annual Marine Corps Marathon to be held on October 27, 2013; an event that sold out in 2 hours and 41 minutes in 2012.
  • We are looking at building “Team BCAN” to not only run in the event and raise awareness for bladder cancer but to raise needed funds for fostering research and patient education. According to the Marine Corps Marathon, there is not a required qualifying time to participate in the event, but all runners should maintain at least a 14 minute mile pace. In order to become a member of “Team BCAN” and officially have a slot in this year’s race, you must be registered through BCAN.
  • No federal or Marine Corps endorsement is implied.
  • If you are interested in becoming a member of BCAN’s team or have any questions, please contact Larry Rzepka, BCAN’s Executive Director, at lrzepka@bcan.org.
  • abhansel.jpg
    Donna Hansel, M.D., Ph.D
    Assistant Professor, Department of Pathology and Laboratory Medicine

    Taussig Cancer Center at Cleveland Clinic

    Dr. Hansel graduated from the Johns Hopkins University and received both her M.D. and Ph.D. from the Johns Hopkins School of Medicine. She completed her residency and fellowship in genitourinary pathology at the Johns Hopkins Hospital and is currently an Assistant Professor of Anatomic Pathology, Urology and the Taussig Cancer Center at the Cleveland Clinic, where she specializes in genitourinary pathology and co-directs the bladder cancer working group. Dr. Hansel’s research focuses on the molecular mechanisms that underlie the development and metastasis of various forms of bladder cancer, including urothelial (transitional cell) carcinoma, squamous cell carcinoma and adenocarcinoma.
    Click here for more information.